Harvest Fund Management Co. Ltd Boosts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Posted by Stanley Muller on Jun 5th, 2026

Harvest Fund Management Co. Ltd lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 15.7% during the fourth quarter, Holdings Channel reports. The fund owned 9,040 shares of the company’s stock after acquiring an additional 1,225 shares during the period. Harvest Fund Management Co. Ltd’s holdings in IDEXX Laboratories were worth $6,116,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of IDXX. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter worth $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories in the fourth quarter valued at $29,000. WealthCollab LLC purchased a new position in IDEXX Laboratories in the second quarter valued at $30,000. Caitong International Asset Management Co. Ltd purchased a new position in IDEXX Laboratories in the third quarter valued at $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.7%

Shares of IDEXX Laboratories stock opened at $564.74 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.55 billion, a PE ratio of 41.59, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. The company has a 50-day moving average of $563.32 and a two-hundred day moving average of $632.63.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the company posted $2.91 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. UBS Group dropped their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Finally, Stifel Nicolaus dropped their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

Get Our Latest Stock Analysis on IDEXX Laboratories

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.